More News

22 May 2017 Teneobio and Poseida Announce License Agreement for the Use of UniDab™ in CAR T-Cell Therapy
22 May 2017 New Research Collaboration between Nektar and Takeda to Explore Combination Cancer Therapy Approaches with NKTR-214, a CD122-Biased Agonist, and Five Takeda Cancer Therapy Compounds
22 May 2017 AstraZeneca enters agreement with Recordati for Seloken in Europe
21 May 2017 Corbin Therapeutics and Proteorex Therapeutics announce a research and development collaboration to discover novel USP15 inhibitors
16 May 2017 Synlogic and Mirna Therapeutics Agree to Merger
16 May 2017 X-Chem and Vertex Enter into Multi-Target Genetic Disease Collaboration
16 May 2017 Beactica Announces Glioblastoma Research Collaboration with Uppsala University and the DDD Platform at SciLifeLab
15 May 2017 Otsuka and Teva Sign Licensing Agreement for Japan on Prophylactic Migraine Drug Candidate Fremanezumab (TEV-48125)
15 May 2017 Immunomic Therapeutics Announces Exclusive License of Phase II Cancer Immunotherapy Technology Targeting Cytomegalovirus (CMV)
15 May 2017 Biogen Acquires Remedy Pharmaceuticals’ CIRARA™ for Large Hemispheric Stroke
15 May 2017 BioNTech Announces Positive Results of an International Reproducibility Study with MammaTyper®
11 May 2017 Zealand Pharma discloses amylin as the biological target under their 2014 agreement with Boehringer Ingelheim
11 May 2017 Sangamo Therapeutics And Pfizer Announce Collaboration For Hemophilia A Gene Therapy
11 May 2017 Oxford Genetics Licenses CRISPR Gene Editing Technology from ERS Genomics to extends its synthetic biology capabilities
10 May 2017 Chugai Enters into a License Agreement for Emicizumab with JW Pharmaceutical
09 May 2017 Corvus Pharmaceuticals and Monash University Enter into Exclusive License Agreement for Novel Immuno-Oncology Program
09 May 2017 Takeda and GammaDelta Therapeutics Announce Collaboration to Advance Tissue-derived gamma delta (γδ) T Cells
09 May 2017 Exscientia Announces EUR250 Million Collaboration for a Multiple-Product Development and Licence Option Agreement with Sanofi
09 May 2017 Feldan Therapeutics and Elasmogen Announce Research Agreement with Amgen to Develop Intracellular Biologics
08 May 2017 CRISPR Therapeutics Announces Exclusive License of Lipid Nanoparticle Technologies Developed at MIT
05 May 2017 Immunomedics Delivers Business Updates, Announces Private Placement Offering and Outlines Strategic Steps to Drive Stockholder Value
05 May 2017 Vivet Therapeutics Raises €37.5 Million in Series A Financing Round to Advance Novel Gene Therapies for Treating Inherited Metabolic Diseases
04 May 2017 Novartis exercises exclusive option agreement with Conatus for the treatment of NASH
03 May 2017 Servier and miRagen extend collaboration for the research, development and commercialization of microRNA-targeting therapeutics
03 May 2017 Selecta Biosciences Obtains License for Recombinant Immunotoxin LMB-100 from National Cancer Institute (NCI) for Pancreatic Cancer, Mesothelioma and Other Cancers

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing